Company profile
Home
Leading an inflammation revolution
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
PSC01 | Transaction MzQ0NDQyOTI0MWFkaXF6a2N4
Published 21 Nov 2024 11:54
PSC09 | Transaction MzQ0NDQyODc3NWFkaXF6a2N4
Published 21 Nov 2024 11:51
SH01 | Transaction MzQ0NDQ2NDk3NGFkaXF6a2N4
Published 21 Nov 2024 05:20
TM01 | Transaction MzQ0NDEwODE5NWFkaXF6a2N4
Published 19 Nov 2024 12:41
TM01 | Transaction MzQ0NDEwODExMGFkaXF6a2N4
Published 19 Nov 2024 12:40
AP01 | Transaction MzQ0NDEwODY1N2FkaXF6a2N4
Published 19 Nov 2024 12:40
TM01 | Transaction MzQ0NDEwODA4M2FkaXF6a2N4
Published 19 Nov 2024 12:39
TM01 | Transaction MzQ0NDEwODI1OWFkaXF6a2N4
Published 19 Nov 2024 12:39
TM01 | Transaction MzQ0NDEwODIwMGFkaXF6a2N4
Published 19 Nov 2024 12:37
Last accounts made up date
Company registered at Companies House
Kynos Therapeutics develops pharmaceuticals designed to treat patients with uncontrolled inflammation.
Shell company formed to allow investment discussions around commercialising our KMO inhibitor portfolio
There has been £12.5m investment in the company including £2.5m from Innovate UK. First in human Phase 1 study underway
Kynos has successfully completed a Phase 1 clinical trial of the lead molecule in humans. We generated significant pharma interest and in Pct 2024 were acquired in a cash sale by Dr Falk Pharma GmbH. Dr Falk have committed resource to a Phase 1 extension and a Phase 2 POC clinical trial in 2025.
Pending
1 Apr 2022 to 31 Jan 2024
Our company, Kynos Therapeutics Ltd., is developing a new kind of medicine to treat diseases caused by inflammation, especially kidney damage after major open heart surgery, and that may also have a use against cancer. This new medicine affects the metabolism of cells and tissues, and especially how cells of the immune system function. Our new medicine ha...
